BMC endocrine disorders · 2026
Continuous glucose monitoring reveals distinct clinical implications of glucose levels at the start and end of hemodialysis in people with type 2 diabetes.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hayashi Akinori, Takaesu Rihito, Sogabe Haruna, Tani Yuiko, Aoki Nagisa, Ko Yoshiki, Tsuji Satoshi, Moriguchi Ibuki, Kobayashi Naoyuki, Miyatsuka Takeshi
Аннотация
BACKGROUND: The clinical significance of glucose levels at the start and end of hemodialysis (HD) sessions in people with type 2 diabetes remains insufficiently explored.
METHODS: We retrospectively analyzed 116 individuals with type 2 diabetes undergoing HD (age 61 ± 12 years; 69% male; HbA1c 6.5 ± 1.3%; glycated albumin 21.1 ± 6.9%). Continuous glucose monitoring (CGM) data were collected from two dialysis institutions to evaluate sensor glucose levels at the start and end of HD sessions and their associations with CGM metrics and hypoglycemia.
RESULTS: Glucose levels were significantly higher at the start than at the end-of-HD (175.6 ± 55.4 mg/dL vs. 118.7 ± 43.3 mg/dL, P < 0.0001), with no correlation (r = 0.095, P = 0.31). Start-of-HD glucose was independently associated with dialysis duration (β = -0.184, P = 0.015) and time above range > 180 mg/dL (TAR180; β = 0.576, P < 0.0001), whereas end-of-HD glucose was associated with glycemic variability (%CV; β = -0.412, P < 0.0001) and TAR180 (β = 0.360, P < 0.0001). HD-induced hypoglycemia occurred in 25 participants (21.6%), including 14 (12.1%) during HD and 22 (19.0%) after HD. Lower end-of-HD glucose was significantly associated with all-cause hypoglycemia (OR 0.97; 0.95-0.98), HD-induced hypoglycemia (OR 0.96; 0.94-0.98), hypoglycemia during HD (OR 0.93; 0.90-0.97), and post-dialysis hypoglycemia (OR 0.95; 0.93-0.98; all P < 0.0001). An end-of-HD glucose level < 90 mg/dL was linked to increased all-cause (76.9% vs. 17.8%) and HD-induced (61.5% vs. 10.0%) hypoglycemia, demonstrating clinically meaningful discrimination for hypoglycemia risk stratification.
CONCLUSION: Glucose levels at the start and end of HD sessions demonstrate distinct clinical relevance. End-of-HD glucose level serves as a useful marker for hypoglycemia risk, highlighting the potential importance of tailored monitoring strategies to support glycemic risk assessment in this high-risk population.
METHODS: We retrospectively analyzed 116 individuals with type 2 diabetes undergoing HD (age 61 ± 12 years; 69% male; HbA1c 6.5 ± 1.3%; glycated albumin 21.1 ± 6.9%). Continuous glucose monitoring (CGM) data were collected from two dialysis institutions to evaluate sensor glucose levels at the start and end of HD sessions and their associations with CGM metrics and hypoglycemia.
RESULTS: Glucose levels were significantly higher at the start than at the end-of-HD (175.6 ± 55.4 mg/dL vs. 118.7 ± 43.3 mg/dL, P < 0.0001), with no correlation (r = 0.095, P = 0.31). Start-of-HD glucose was independently associated with dialysis duration (β = -0.184, P = 0.015) and time above range > 180 mg/dL (TAR180; β = 0.576, P < 0.0001), whereas end-of-HD glucose was associated with glycemic variability (%CV; β = -0.412, P < 0.0001) and TAR180 (β = 0.360, P < 0.0001). HD-induced hypoglycemia occurred in 25 participants (21.6%), including 14 (12.1%) during HD and 22 (19.0%) after HD. Lower end-of-HD glucose was significantly associated with all-cause hypoglycemia (OR 0.97; 0.95-0.98), HD-induced hypoglycemia (OR 0.96; 0.94-0.98), hypoglycemia during HD (OR 0.93; 0.90-0.97), and post-dialysis hypoglycemia (OR 0.95; 0.93-0.98; all P < 0.0001). An end-of-HD glucose level < 90 mg/dL was linked to increased all-cause (76.9% vs. 17.8%) and HD-induced (61.5% vs. 10.0%) hypoglycemia, demonstrating clinically meaningful discrimination for hypoglycemia risk stratification.
CONCLUSION: Glucose levels at the start and end of HD sessions demonstrate distinct clinical relevance. End-of-HD glucose level serves as a useful marker for hypoglycemia risk, highlighting the potential importance of tailored monitoring strategies to support glycemic risk assessment in this high-risk population.